Pomerantz LLP is investigating claims against Encompass Health Corporation following a New York Times article that reported below-average safety performance and preventable patient readmissions at Encompass-owned hospitals. The article highlighted serious mistakes leading to patient fatalities and cited 34 facilities with significantly worse Medicare ratings. After the report, Encompass's stock price dropped over 10%. The investigation focuses on whether Encompass and its executives engaged in securities fraud or unlawful practices, potentially leading to a class action lawsuit.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
NVIDIA and Noetra Corp. are partnering to build Japan's first national AI infrastructure, the NVIDIA Vera Rubin AI factory, featuring 13,750 Vera CPUs and 27,500 Rubin GPUs. Supported by Japan's Ministry of Economy, Trade and Industry, this 140-megaw...
Solana (SOL) has gained about 30% from its June low, trading around $78 and surpassing its 50-day EMA. The token's upward momentum is supported by increased speculative trading and a new SuperTrend buy signal, the first since October 2025. However, i...
Kenmare Resources reported weaker-than-expected production in the first half of 2026 due to commissioning delays at its Wet Concentrator Plant A, with ilmenite output down 40% year on year in Q2. Despite this, shipments increased by 53% as the compan...
